Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha

Xenobiotica

Volumn 43, Issue 11, 2013, Pages 963-972

  Kalgutkar, Amit S ^a   Chen, Danny ^a   Varma, Manthena V ^a   Feng, Bo ^a   Terra, Steven G ^a   Scialis, Renato J ^a   Rotter, Charles J ^a   Frederick, Kosea S ^a,b   West, Mark A ^a   Goosen, Theunis C ^a   Gosset, James R ^a   Walsky, Robert L ^a,c   Francone, Omar L ^a,d  

^a PFIZER INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Shire Pharmaceuticals   (United States)

Author keywords

Carboxylic acid; CYP; DDI; Human; Inhibitor; OATP; Pharmacokinetics; PPAR

Indexed keywords

5 [N [4 [(4 ETHYLBENZYL)THIO] PHENYL]SULFAMOYL] 2 METHYL BENZOIC ACID; ATORVASTATIN; CP 778 875; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERACTION; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; METABOLITE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BENZOATES; BENZOIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; HEK293 CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYLATION; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE TRANSPORT PROTEINS; OXIDATION-REDUCTION; PPAR ALPHA; PYRROLES; SULFONAMIDES; TIME FACTORS;

EID: 84885087003     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.791004     Document Type: Article

References (35)

1. Asberg A, Hartmann A, Fjeldsa° E, et al. (2001). Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382-6
2. Chen C, Mireles RJ, Campbell SD, et al. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-46
3. Choi MK, Shin HJ, Choi YL, et al. (2011). Differential effect of genetic variants of Na(θ)-Taurocholate co-Transporting polypeptide (NTCP) and organic anion-Transporting polypeptide (NTCP) and organic anion-Transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41:24-34
4. Di L, Whitney-Pickett C, Umland JP, et al. (2011). Development of a new permeability assay using low-efflux MDCK II cells. J Pharm Sci 100:4974-85
5. Duval C, Müller M, Kersten S. (2007). PPAR alpha and dyslipidemia. Biochim Biophys Acta 1771:961-71
6. Feng B, Obach RS, Burstein AH, et al. (2008). Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: An in vitro-in vivo study. Clin Pharmacol Ther 83:567-76
7. Feng B, Xu JJ, Bi YA, et al. (2009). Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci 108:492-500
8. Frederick KS, Maurer TS, Kalgutkar AS, et al. (2009). Pharmacokinetics, disposition and lipid-modulating activity of 5-{2- [4-(3,4-difluorophenoxy)- phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-Activated receptor alpha agonist in preclinical species and human. Xenobiotica 39:766-81
9. Giri N, Agarwal S, Shaik N, et al. (2009). Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: Consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 37:560-70
10. Gleeson MP, Davis AM, Chohan KK, et al. (2007). Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 21:559-73
11. Grube M, Köck K, Oswald S, et al. (2006). Organic anion transporting polypeptide 2B1 is a high-Affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80:607-20
12. Hermann M, Asberg A, Christensen H, et al. (2004). Substantially elevated levels of atorvastatin and metabolites in cyclosporine-Treated renal transplant recipients. Clin Pharmacol Ther 76:388-91
13. Hirano M, Maeda K, Matsushima S, et al. (2005). Involvement of BCRP (ABCG2) in the biliary excretion of pitvastatin. Mol Pharmacol 68: 800-7
14. Holtzman CW, Wiggins BS, Spinler SA. (2006). Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601-7
15. Hsiang B, Zhu Y, Wang Z, et al. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liverspecific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-8
16. International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nature Rev Drug Discov 9:215-36
17. Jacobsen W, Kuhn B, Soldner A, et al. (2000). Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369-78
18. Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705
19. Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug-drug interactions. J Med Chem 55:4740-63
20. Kato M, Shitara Y, Sato H, et al. (2008). The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-901
21. Lau YY, Okochi H, Huang Y, et al. (2006). Multiple transporters affect the disposition of atorvastatin and its two active hydroxyl metabolites: Application of in vitro and ex situ systems. J Pharmacol Exp Ther 316: 762-71
22. Lau YY, Huang Y, Frassetto L, et al. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204
23. Lennernäs H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-60
24. Li J, Volpe DA, Wang Y, et al. (2011). Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39:1196-202
25. Maeda K, Ikeda Y, Fujita T, et al. (2011). Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90: 575-81
26. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-81
27. Niessen J, Jedlitschky G, Grube M, et al. (2009). Human platelets express organic anion-Transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 37:1129-37
28. Pettersen JC, Pruimboom-Brees I, Francone OL, et al. (2012). The PPARa agonists fenofibrate and CP-778875 cause increased b-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. Toxicol Pathol 40:435-47
29. Shah A, Radar DJ, Millar JS. (2010). The effect of PPAR-Alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 210:35-40
30. Tenenbaum A, Fisman EZ. (2012). Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 11: 125. doi: 10.1186/1475-2840-11-125
31. Varma MV, Chang G, Lai Y, et al. (2012a). Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos 40:1527-37
32. Varma MV, Lai Y, Feng B, et al. (2012b). Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860-73
33. Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-60
34. Yao M, Zhang H, Chong S, et al. (2003). A rapid and sensitive LC/MS/ MS assay for quantitative determination of digoxin in rat plasma. J Pharm Biomed Anal 32:1189-97
35. Yang SH, Choi JS, Choi DH. (2011). Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: Possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1-9